Posters

Canaloplasty without suture placement for the treatment of open-angle glaucoma: three year outcomes

Poster Details

First Author: M.Khaimi USA

Co Author(s):                        

Abstract Details

Purpose:

To evaluate the three-year safety and efficacy outcomes of canaloplasty without suture placement to reduce intraocular pressure (IOP) and glaucoma medication dependence in patients with open-angle glaucoma.

Setting:

Dean McGee Eye Institute, University of Oklahoma, Oklahoma, United States.

Methods:

A single-center, retrospective chart analysis of 33 open-angle glaucoma patients who underwent a modified version of conventional (ab-externo) canaloplasty, without placement of tension suture. Patients included in this analysis had primary open-angle glaucoma, pigmentary glaucoma or exfoliative glaucoma. Exclusion criteria were: patients who had undergone more than two laser trabeculoplasties, had neovascular disease, uveitis, peripheral anterior synechiae, angle recession, and/or developmental/secondary glaucoma. The primary endpoints were mean IOP and mean number of anti-glaucoma medications at 1, 3, 6, 12, 18, 24 and 36 months. Intra- and postoperative complication rates were also assessed as a secondary endpoint.

Results:

There were statistically significant reductions in both IOP and medication use in the postoperative follow-up. Mean IOP reduced from 21.4 mm Hg at baseline to 15.1 mm Hg (p<.001), 13.3 mm Hg (p<0.001) and 11.0 mm Hg (p<0.006) at 1, 2 and 3 years respectively. The number of medications being used by each patient fell from a mean of 2.2 preoperatively to 1.0 at 1 year (p<0.001), 1.1 at 2 years (p=0.012) and 0.7 at 3 years (p=0.003). Incidences of intra- and post-operative complications were low, and no serious adverse events recorded.

Conclusions:

This analysis demonstrates that canaloplasty, without suture placement, effectively reduces long-term IOP and anti-glaucoma medication dependence in patients with open-angle glaucoma. The technique provides a good clinical option for glaucoma patients unmanaged by medication alone, as a result of its favorable safety profile and efficacy.

Financial Disclosure:

receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented